Eli Lilly and Company

Eli Lilly & Company, founded in 1876 and headquartered in Indianapolis, Indiana, is a prominent American pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products. The company operates in various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology, with key products such as Zyprexa, Cymbalta, Humalog, and Verzenio. Eli Lilly's products are distributed in approximately 135 countries, with manufacturing facilities in the United States, Puerto Rico, and 25 other nations. In addition to its commercial endeavors, the Eli Lilly & Company Foundation supports initiatives aimed at improving patient outcomes and educational opportunities for underserved communities, particularly in early childhood education and STEM fields.

Andrew Adams

Senior Vice President, Neurodegeneration Research and Genetic Medicine

Anat Ashkenazi

CFO

Gordon Brooks

Interim CFO

Teresa Millan

Corporate Affairs Director

Pascal Qian

Vice President

Diogo Rau

Executive Vice President and Chief Information and Digital Officer

Melissa Seymour

Executive VP of Global Quality

Past deals in Distressed

Disarm Therapeutics

Acquisition in 2020
Disarm Therapeutics is a biotechnology company focused on developing disease-modifying therapeutics for patients suffering from neurological diseases characterized by axonal degeneration. Founded in 2016 and based in Cambridge, Massachusetts, the company aims to prevent axon loss and address conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Its innovative approach allows for the treatment of acute diseases affecting the central, ocular, and peripheral nervous systems. As of October 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.